TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7004400

Group type: EXPERIMENTAL
Intervention: Stapled anastomoses
Number of subjects: 51

Group type: COMPARATOR
Intervention: Hand sutures
Number of subjects: 51
Study: 31409381

Group type: EXPERIMENTAL
Intervention: PA-first arm (4-week PA intervention followed by 4-week FVC intervention)
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: FVC-first arm (4-week FVC intervention followed by 4-week PA intervention)
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: PA + FVC simultaneous arm (8-week intervention addressing both PA and FVC)
Number of subjects: 556

Group type: COMPARATOR
Intervention: Placebo-control arm (8 weeks of general health information)
Number of subjects: 556
Study: 28861803

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) treatment
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Psychological intervention (PI)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 32
Study: 24209774

Group type: EXPERIMENTAL
Intervention: alpha‐methyl‐para‐tyrosine (AMPT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 23646916

Group type: EXPERIMENTAL
Intervention: Matching interviewer‐interviewee instructions (providing or obtaining as much information as possible or only accurate information) in Experiment 1.
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Access to corroborating eyewitness identifications in Experiment 2.
Number of subjects: 83
Study: 21771668

Group type: EXPERIMENTAL
Intervention: OM-85 BV (bacterial lysate prophylaxis)
Number of subjects: 63

Group type: COMPARATOR
Intervention: No prophylactic regimen (Control)
Number of subjects: 63
Study: 19390752

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) 800 mg/day
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 17551159

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 4447

Group type: COMPARATOR
Intervention: Control (metformin plus sulfonylurea)
Number of subjects: 4447
Study: 15167084

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.15 mg/kg b.i.d.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.30 mg/kg b.i.d.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.60 mg/kg b.i.d.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 11446724

Group type: EXPERIMENTAL
Intervention: Potassium supplementation (60 mmol potassium chloride)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 9786373

Group type: EXPERIMENTAL
Intervention: Nurse home visitation during pregnancy and postnatally
Number of subjects: 315
Study: 8169187

Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg caffeine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 5.0 mg/kg caffeine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Caffeine (both dosages)
Number of subjects: 21
Study: 3477659

Group type: EXPERIMENTAL
Intervention: Retinol (15 mg or 50,000 IU), riboflavin (200 mg), and zinc (50 mg)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Retinol, riboflavin, and zinc
Number of subjects: 610
Study: 28936715

Group type: EXPERIMENTAL
Intervention: Action-line partograph
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Stepped-line partograph
Number of subjects: 384
Study: 28183047

Group type: EXPERIMENTAL
Intervention: 900 mg of an ellagitannin-containing pomegranate extract (PE) daily
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 35
Study: 26322819

Group type: EXPERIMENTAL
Intervention: Continuous pulse oximetry monitoring
Number of subjects: 161

Group type: COMPARATOR
Intervention: Intermittent pulse oximetry monitoring
Number of subjects: 161
Study: 22832034

Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole 10 mg (6-11 years)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole 40 mg (12-17 years)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole 0.5 mg/kg (0-1 month)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole (various doses)
Number of subjects: 59
Study: 19884642

Group type: EXPERIMENTAL
Intervention: Lower intensity RPSS (2-hour sessions, 3 times a week for 1 month)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Higher intensity RPSS (2-hour sessions, 3 times a week for 1 month)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Lower intensity RPSS
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Higher intensity RPSS
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: RPSS (both intensities)
Number of subjects: 22
Study: 17392726

Group type: EXPERIMENTAL
Intervention: Naloxone 0.01 mg/kg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone 0.3 mg/kg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.15 mcg/kg/min
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Number of subjects: 13
Study: 16372226

Group type: EXPERIMENTAL
Intervention: Moderate-fat/moderate-carbohydrate diet
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low-fat/high-carbohydrate diet
Number of subjects: 40
Study: 12065339

Group type: EXPERIMENTAL
Intervention: Clarithromycin, 500 mg bid for 6 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 9469367

Group type: EXPERIMENTAL
Intervention: Single-dose oral granisetron (2 mg)
Number of subjects: 1085

Group type: COMPARATOR
Intervention: Intravenous ondansetron (32 mg)
Number of subjects: 1085
Study: 7648772

Group type: EXPERIMENTAL
Intervention: Entacapone (400 mg single dose)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: COMPARATOR
Intervention: Entacapone and Placebo
Number of subjects: 11
Study: 2652209

Group type: EXPERIMENTAL
Intervention: Systematic antibiotic prophylaxis for 48 h with sodium cefuroxim, 1.5 g the first dose and subsequent doses of 750 mg iv
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Selective antibiotic prophylaxis based on determination of preoperative gastric pH (pH < 4, no antibiotic prophylaxis; pH > 4, prophylaxis as in group I)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy beginning postoperatively with cefuroxim 750 mg every 78 h for 4 days
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control group (no specific prophylaxis mentioned)
Number of subjects: 179
Study: 817696

Group type: EXPERIMENTAL
Intervention: Clonazepam (3 to 6 mg daily) combined with previous antiepileptic drugs
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo combined with previous antiepileptic drugs
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 20
Study: 31842788

Group type: EXPERIMENTAL
Intervention: Continuous suture
Number of subjects: 134

Group type: COMPARATOR
Intervention: Interrupted sutures
Number of subjects: 134
Study: 30355322

Group type: EXPERIMENTAL
Intervention: AADvac1 (active immunotherapy against tau protein pathology)
Number of subjects: 26
Study: 27119580

Group type: EXPERIMENTAL
Intervention: Insulin lispro 200 U/mL (IL200)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Insulin lispro 100 U/mL (IL100)
Number of subjects: 38
Study: 24520362

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (3 times a week for 4 weeks)
Number of subjects: 28
Study: 22205311

Group type: EXPERIMENTAL
Intervention: Sucrose-sweetened soft drinks (SSSDs) (regular cola)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Isocaloric semiskim milk
Number of subjects: 47

Group type: COMPARATOR
Intervention: Aspartame-sweetened diet cola
Number of subjects: 47

Group type: COMPARATOR
Intervention: Water
Number of subjects: 47
Study: 20695726

Group type: EXPERIMENTAL
Intervention: 18-core biopsy
Number of subjects: 233

Group type: COMPARATOR
Intervention: 12-core biopsy
Number of subjects: 233
Study: 17481947

Group type: EXPERIMENTAL
Intervention: Optimal therapy for advanced chronic heart failure (specific intervention details not provided)
Number of subjects: 0
Study: 15795448

Group type: EXPERIMENTAL
Intervention: Iron intake in women using HRT
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Calcium intake in women not using HRT
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Iron intake in women using HRT in the lowest tertile of calcium intake
Number of subjects: 228
Study: 12070751

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 27
Study: 10456339

Group type: EXPERIMENTAL
Intervention: Living Skin Equivalent (LSE)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Autograft
Number of subjects: 20

Group type: COMPARATOR
Intervention: PUF (Polyurethane Film) occlusive dressing
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LSE
Number of subjects: 20

Group type: COMPARATOR
Intervention: PUF
Number of subjects: 20
Study: 7880791

Group type: EXPERIMENTAL
Intervention: Topical fusidic acid gel (Fucithalmic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral oxytetracycline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of fusidic acid gel and oxytetracycline
Number of subjects: 0
Study: 2245455

Group type: EXPERIMENTAL
Intervention: Nicardipine (20 mg twice a day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 386974

Group type: EXPERIMENTAL
Intervention: 50 mg propylthiouracil every two hours (group A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 100 mg, 100 mg, and 150 mg propylthiouracil at 8 hour intervals (group B)
Number of subjects: 24
Study: 31171876

Group type: EXPERIMENTAL
Intervention: Atezolizumab + cobimetinib + vemurafenib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cobimetinib + vemurafenib (run-in period)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vemurafenib (run-in period)
Number of subjects: 0
Study: 28794054

Group type: EXPERIMENTAL
Intervention: Random survival forests technique
Number of subjects: 6814
Study: 25724571

Group type: EXPERIMENTAL
Intervention: Diverse interventions including improved communication, changes in workflow, and targeted quality improvement (QI) projects
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Workflow interventions
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Targeted QI projects
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Interventions in communication or workflow
Number of subjects: 166
Study: 23514874

Group type: EXPERIMENTAL
Intervention: Continuous epidural anesthesia with ropivacaine, fentanyl, and epinephrine
Number of subjects: 85

Group type: COMPARATOR
Intervention: General anesthesia with sevoflurane and fentanyl, and systemically administered opioids
Number of subjects: 85
Study: 21199979

Group type: EXPERIMENTAL
Intervention: Video Interaction Project (VIP)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Building Blocks (BB)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Control
Number of subjects: 410
Study: 19144532

Group type: EXPERIMENTAL
Intervention: Ambroxol (1000 mg/day by intravenous infusion on the day of operation and on the first 3 postoperative days)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Fluid therapy only without ambroxol
Number of subjects: 140
Study: 16670830

Group type: EXPERIMENTAL
Intervention: Action potential simulation (APS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo APS
Number of subjects: 10
Study: 16004778

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intensive insulin therapy)
Number of subjects: 40
Study: 11695212

Group type: EXPERIMENTAL
Intervention: Colgate Total Plus Whitening Toothpaste
Number of subjects: 93

Group type: COMPARATOR
Intervention: Colgate Total Toothpaste
Number of subjects: 93
Study: 9790365

Group type: EXPERIMENTAL
Intervention: Serial membrane sweeping every 3 days
Number of subjects: 65

Group type: COMPARATOR
Intervention: Gentle examinations every 3 days (Control)
Number of subjects: 65
Study: 8085180

Group type: EXPERIMENTAL
Intervention: 1-month, 6-month, and 1-year prevalence rates for mental disorders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol abuse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol dependence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Depressive disorders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anxiety disorders
Number of subjects: 0
Study: 2681508

Group type: COMPARATOR
Intervention: Cholestyramine 12 g b.i.d.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg q.p.m.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination therapy (Simvastatin + Cholestyramine)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Simvastatin monotherapy after 52 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 20
Study: 1251131

Group type: EXPERIMENTAL
Intervention: Prednisone treatment
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Taxonomic classification
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Clinical classifications based on sex, alcoholism, and compensation
Number of subjects: 441

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 441
Study: 31937344

Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy (APM)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo-surgery
Number of subjects: 146
Study: 30195601

Group type: EXPERIMENTAL
Intervention: Modified nerve-sparing thoracotomy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard posterolateral thoracotomy (control)
Number of subjects: 90
Study: 28410617

Group type: EXPERIMENTAL
Intervention: n-3 PUFAs (2 g/day for 3 months)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 26118567

Group type: EXPERIMENTAL
Intervention: Cemented TKA
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cementless TKA
Number of subjects: 100
Study: 24069844

Group type: EXPERIMENTAL
Intervention: Enamel Matrix Derivative (EMD) applied after Scaling and Root Planing (SRP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Scaling and Root Planing (SRP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing (SRP) combined with EMD
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Non-surgical therapy with EMD
Number of subjects: 20
Study: 21739692

Group type: EXPERIMENTAL
Intervention: Acupoint catgut-embedding combined western medicine (ACCWM)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Simple western medicine (WM)
Number of subjects: 52
Study: 19699861

Group type: EXPERIMENTAL
Intervention: nano-cTnI assay
Number of subjects: 100

Group type: COMPARATOR
Intervention: current-generation cTnI
Number of subjects: 100
Study: 16714961

Group type: EXPERIMENTAL
Intervention: Brief focal ultrasound followed by a 5-minute application of a 4% lidocaine topical anesthetic
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 77
Study: 15020185

Group type: COMPARATOR
Intervention: bupropion
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: not smoking menthol cigarettes
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: smoking after 30 min of waking
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: older age
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: smoking fewer cigarettes per day
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: lower cotinine levels
Number of subjects: 600
Study: 11323371

Group type: EXPERIMENTAL
Intervention: Diltiazem (10 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 9293935

Group type: EXPERIMENTAL
Intervention: Intraoperative intermittent sequential compression (ISC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no ISC)
Number of subjects: 50
Study: 8123895

Group type: EXPERIMENTAL
Intervention: 6 MU IFN
Number of subjects: 81

Group type: COMPARATOR
Intervention: 3 MU IFN
Number of subjects: 81
Study: 3621341

Group type: EXPERIMENTAL
Intervention: Superflow (5F) catheter
Number of subjects: 34

Group type: COMPARATOR
Intervention: 8F catheter
Number of subjects: 34
Study: 31128267

Group type: EXPERIMENTAL
Intervention: Citalopram (CTP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30302147

Group type: EXPERIMENTAL
Intervention: Subxiphoid port
Number of subjects: 182

Group type: COMPARATOR
Intervention: Umbilical port
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 182
Study: 27199121

Group type: EXPERIMENTAL
Intervention: nebivolol (5-20 mg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: metoprolol succinate (100-300 mg/day)
Number of subjects: 25
Study: 25701829

Group type: EXPERIMENTAL
Intervention: Nicorandil 10 mg, 2 times a day (n = 27)
Number of subjects: 54
Study: 23412897

Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) at 15 liters/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) at 30 liters/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) at 45 liters/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) during sleep at 15 liters/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) during sleep at 30 liters/min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 10
Study: 19451137

Group type: EXPERIMENTAL
Intervention: COBRA combination therapy (step-down prednisolone, methotrexate, and sulfasalazine)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Sulfasalazine (SSZ) monotherapy
Number of subjects: 155
Study: 18193385

Group type: EXPERIMENTAL
Intervention: Teicoplanin (800 mg on day 1, then 400 mg/day) + piperacillin/tazobactam + gentamicin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vancomycin (2 g/day) + meropenem + levofloxacin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Teicoplanin with amphotericin B
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vancomycin with amphotericin B
Number of subjects: 100
Study: 17106142

Group type: EXPERIMENTAL
Intervention: Candesartan (4 mg, most frequent dose)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 157

Group type: COMPARATOR
Intervention: ACEI (lisinopril, enalapril, trandolapril)
Number of subjects: 157
Study: 12612168

Group type: EXPERIMENTAL
Intervention: Protein supplements with supplemental calcium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total protein intake with supplemental calcium citrate malate and vitamin D
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11778479

Group type: EXPERIMENTAL
Intervention: Modified two ways connection
Number of subjects: 7

Group type: COMPARATOR
Intervention: Conventional set-up
Number of subjects: 7
Study: 8632120

Group type: EXPERIMENTAL
Intervention: Zinc acetate 10 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Zinc acetate 25 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Zinc acetate 50 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Zinc acetate 100 mg
Number of subjects: 11
Study: 1600852

Group type: EXPERIMENTAL
Intervention: Nilvadipine (8 mg per day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Captopril (75 mg per day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nilvadipine and Captopril
Number of subjects: 18
Study: 2866789

Group type: EXPERIMENTAL
Intervention: Timolol 1% eyedrops
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: L-714,465 1% eyedrops
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (methyl-cellulose)
Number of subjects: 6
Study: 29797713

Group type: EXPERIMENTAL
Intervention: 2 cm syringes
Number of subjects: 30

Group type: COMPARATOR
Intervention: 2 cm cups
Number of subjects: 30
Study: 27281645

Group type: EXPERIMENTAL
Intervention: Alcohol-based hand sanitizer in strategic workplace locations and personal use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brief hand hygiene education
Number of subjects: 0
Study: 24520097

Group type: EXPERIMENTAL
Intervention: PAM50 risk-of-recurrence (ROR) score
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: PAM50 ROR-based risk groups
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Low ROR-based risk group
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: High ROR-based risk group
Number of subjects: 1246
Study: 22456954

Group type: EXPERIMENTAL
Intervention: Date palm immunotherapy (IT) for 15 months
Number of subjects: 30
Study: 19860762

Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg
Number of subjects: 525

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 525
Study: 18565853

Group type: EXPERIMENTAL
Intervention: Clofarabine plus low-dose cytarabine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Clofarabine alone
Number of subjects: 70
Study: 15823640

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 3140

Group type: EXPERIMENTAL
Intervention: switching to rosuvastatin 10 mg from atorvastatin 10 mg, simvastatin 20 mg, and pravastatin 40 mg
Number of subjects: 3140

Group type: EXPERIMENTAL
Intervention: switching to rosuvastatin 20 mg from atorvastatin 20 mg
Number of subjects: 3140

Group type: EXPERIMENTAL
Intervention: switching to rosuvastatin 10 mg from atorvastatin 20 mg
Number of subjects: 3140
Study: 12874270

Group type: EXPERIMENTAL
Intervention: Chemotherapy (etoposide plus cisplatin) plus daily radiation therapy (RT)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Chemotherapy (etoposide plus cisplatin) plus split-course radiation therapy (RT) bid
Number of subjects: 246
Study: 10381769

Group type: EXPERIMENTAL
Intervention: 125 mg MDMA
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 75 mg MDMA
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 40 mg amphetamine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9345413

Group type: EXPERIMENTAL
Intervention: Chimeric monoclonal anti-CD4 antibodies
Number of subjects: 0
Study: 1879990

Group type: EXPERIMENTAL
Intervention: Netilmicin (5 mg/kg intramuscularly)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Amikacin (15 mg/kg intramuscularly)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Fosfomycin (3 g per os)
Number of subjects: 96